BRCA1 germline pathogenic variants in advanced epithelial ovarian carcinoma (incl. fallop...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-BRCA1-GERMLINE-OVARIAN |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-OVARIAN |
| Sources | SRC-CIVIC SRC-ESMO-OVARIAN-2024 SRC-NCCN-OVARIAN-2025 |
Actionability Facts
| Biomarker | BIO-BRCA1-BRCA2-GERMLINE |
|---|---|
| Variant | BRCA1 germline pathogenic |
| Disease | DIS-OVARIAN |
| ESCAT tier | IA |
| Recommended combinations | olaparib monotherapy maintenance, niraparib monotherapy maintenance, rucaparib monotherapy maintenance, olaparib + bevacizumab (PAOLA-1, HRD+) |
| Evidence summary | BRCA1 germline pathogenic variants in advanced epithelial ovarian carcinoma (incl. fallopian-tube and primary peritoneal): olaparib maintenance after platinum-response in 1L (SOLO1, Moore 2018) yields ~70% reduction in progression risk; niraparib (NOVA, Mirza 2016) and rucaparib (ARIEL3) extend PFS in platinum-sensitive recurrence. ESCAT IA / OncoKB Level 1. |
Notes
Germline finding mandates cascade testing for first-degree relatives. Includes primary peritoneal and fallopian-tube carcinomas (treated as ovarian- equivalent). PAOLA-1 supports olaparib+bev in HRD-positive (BRCA-mutant subset benefits most).
Used By
No reverse references found in the YAML corpus.